Many governments are woefully unprepared for an epidemic of dementia currently affecting 44 million people worldwide and set to more than treble to 135 million people by 2050, health experts and campaigners said on Thursday.
Pfizer, the largest U.S. pharmaceutical company, said it hoped the enhanced access to its data will help spur further scientific and medical research as well as encourage more patients to get involved in clinical trials.
In a statement released by her attorney on Tuesday night, Huber said, nike shoes “I stand by the rigor of my scientific analysis and I shall continue to follow-up on the concerns that I expressed with regard to Provenge” in the 2012 JNCI paper.
The SEC settlement bars her from the securities industry for six months and requires her to pay a $25,000 fine.
The SEC’s administrative finding, dated last week, concluded that, for a short period of time, Huber had a significant financial stake in the perception of Dendreon.
Leaders from the Group of Eight (G8) industrialized countries are due to meet in London next week for a special summit on dementia – a condition that includes Alzheimer’s, vascular dementia, dementia with Lewy bodies (DLB), shop nike free fronto-temporal dementia and many other causes of cognitive decline.
In Britain, dementia is the most feared health condition among people aged over 55 and costs the economy 23 billion pounds ($37.6 billion) a year – more than cancer, stroke or heart disease combined.
Prime Minister David Cameron, who will host the summit, has committed to spending 66 million pounds on dementia research by 2015. Campaigners welcome the investment, but also say it is a fraction – one eighth – of what is spent on cancer research in Britain.
“As far as changing the mindset of patients getting involved in clinical trials, which has always been a challenge, this will help quite a bit,” free run Romano predicted.
The move comes at a time of increasing pressure on the pharmaceutical industry to be more transparent with clinical trial information – including safety data and details of failed studies – and to increase access for the scientific community.
“Lack of funding means dementia research is falling behind other conditions,” said Jeremy Hughes, chief executive of the Alzheimer’s Society. “The G8 is our once-in-a-generation chance to conquer this condition and we must see meaningful action after the talking is over.”
As well as more money for fundamental scientific research and for drug development, experts say they want the G8 summit to focus on ways to attract, develop and retain the best scientists, doctors and carers into the field of dementia.
http://normallife.tblog.com/post/1971174486